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Introduction
The demands on clinical chemistry laboratories over the last
two decades have grown so rapidly that automated multiple
analysis upon single samples is now the only practicable
method of providing a routine clinical chemistry service in
all but the smallest hospitals. A large variety of equipment is
commercially available for performing this task rapidly and
economically,whilst maintaining high standards of analytical
quality. Any new instrument must therefore equal or better
the established standards of precision, and must use analytical
methods producing results as close as possible to reference
methods for each analyte.
Thework which follows sets out to determine the precision
and accuracy of the Greiner G300 analyser in routine use
and to examine both the analytical capability of the instru-
ment and also the contribution it can make towards handling
the workload of the clinical chemistry laboratory.
The Greiner G300 analyser is a third-generation instrument,
which essentially comprises up-dated modifications of the
Greiner Selective Analyser (GSA II) which has been available
for six years. In the United Kingdom, the GSA II was first
formally evaluated by Skinner and Wilding [I] in 1975, and
a more comprehensive evaluation has recently been produced
by Carlyle et al [2] who made their study over a considerable
period of routine use.
The present evaluation was planned as a rapid assessment
of the clinical utility of the new.G300. Following exhibition
at the 3rd European Congress of Clinical Chemistry (Brighton,
June 1979), a prototype instrument was transported to
Cambridge and was operational for this clinical trial the day
after arrival. Over the next five days a series of experiments
designed to rapidly assess the per-formance of the G300
under routine conditions was performed.
Instrument description
The instrument is a discrete analytical system capable of
performing up to 30 different analyses on a single specimen.
Methods for 20 analyses are already fully documented, and
the repertoire is being extended by further tests as they are
adapted to the G300 from the GSA II.
The G300 is physically smaller than the GSA II and has
improved process control facilities. The number of analyses
on each specimen and the rate of analysis remain the same,
but the handling of emergency and paediatric samples is
faster and more convenient than on the GSA II. A washing
cycle for process tubes is a new feature of the G300 and
contrasts advantageously to the disposable process tubes
used by the GSA II. Carlyle et al [2] found that the cost of
process tubes considerably exceeded the cost of reagents
for most tests, therefore .the economic saving is appreciable.
The G300 comprises a 30 place sample carrier and sampling
unit, a conveyor belt system on which the process tubes
used for reactions are supported and moved, and a ighoto-
meter unit with associated electronics. The analysis time
from sampling to measurement of the final optical density
is 13.4 minutes. The reaction time is variable between 36
seconds and 12.6 minutes according to the position of the
reagent dispensers within the incubator unit, and the optical
density may be read at the wavelength of any one of eight
mercury lines, between 334 and 623 nm. The same sample
can be dispensed into a pair of process tubes, and up to four
different reagents added to each tube. In this manner blank
measurements can be determined when required. The oper-
ator selects the tests to be performed on each specimen by
means of a keyboard next to the sample tray. Commonly-
requested groups of analyses (biochemical profiles) can be
selected by means of a single key, and some examples of
profiling rates are shown in Table 1. It is possible to intro-
duce any urgent investigation into the middle of the batch
of other analyses, or to perform only a few necessary tests
on a small sample of serum, while performing a wider profile
on the remainder of the batch. Emergency samples are placed
in the next available space in the sample tray, the operator
identifies the sample as an emergency, and keys in the test
required: the instrument then positions the emergency
samples under the sampling unit, samples sufficient serum
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for the tests required and then returns to its previous position
in the batch of routine analyses.
Although a flame photometer is available for the G300,
it was not supplied with the instrument and therefore not
evaluated.
The sampling unit has a level sensor, in order that the
sample aspirating tube always dips approximately 2 mm
below the surface of the liquid in the sample cup. Centrifuged
blood samples with the cells still in the tube can be introduced
directly onto the machine, provided appropriate sample
tubes are used. Since no transfer of serum to other containers
is required mistakes in specimen identification are reduced.
The instrument and its methods are designed to work on
an absolute basis, calculating results from pre-set parameters
and the molar absorptivity of the compound formed when
purified standard substrates are reacted in the G300. Contin-
uous use of controls and standards is not required. The
instrument did not need recalibration during the five working
days that it was evaluated in this laboratory. However,
factors can be adjusted if required via the keyboard, but this
is only usually necessary on changing .batches of certain
reagents. All results are calculated according to the general
formula:
FV C=(A2 A1) x- x- x’}- x D
where,
C concentration
E- molar absorptivity of chromogen obtained from
purified standard
FV final volume
SV sample volume
A2 test absorbance
A blank absorbance
D dilution
reaction time
It is important to view the precision data and the speed of
the analyser in the light of the knowledge that all specimens
are patient specimens, and recalibration every tenth specimen
is unnecessary. Throughput is therefore improved by approxi-
mately 11% in relation to using continuous-flow instruments.
Table 1. Analysis rate of G300 for commonly requested
"profiles"
Tests Requested
Cholesterol +
triglyceride
Sodium, potassium,
glucose, total CO2,
urea, creatinine.
Calcium, phosphate,
total protein, ALT,
albumin, bilirubin,
alkaline phosphatase.
R,ate
(specimen/hour)
150
43
30
Total Analytical time for:
sample
(min)
13.8
14.8
15.4
10 samples
(min)
16.4
27.4
33.4
Analytical methods
The G300 was evaluated when performing assays for albumin,
alkaline phosphatase, calcium, creatinine, glucose, magnesium,
total bilirubin, total CO2, total protein, triglyceride and urea.
Brief details of the methods employed, and those used for
the comparative accuracy study are shown in Table 2. All of
tile methods used were recommended by the manufacturer
of the instrument concerned (Greiner Electronics Ltd.,
Technicon Instruments Corporation and Pye Unicam Ltd.)
and all reagents except those for the analysis of glucose
(Boehringer Corporation) and triglyceride (Dow Diagnostics
for the G300, BDH Chemicals for continuous flow) were also
supplied by the equipment manufacturer.
Appraisal protocol
The study was designed to give a rapid assessment of the
precision, carryover, comparative accuracy and general
performance of the G300 in routine use. Precision has been
studied at varying levels of analyte concentration for eleven
determinations, and comparative accuracy has been examined
by comparison of results of patient and control samples
analysed on the G300 with results given by the methods
Table 2. Methods employed on G300 and AutoAnalyser during evaluation
Analysis
Albumin
Alkaline
Phosphatase
Calcium
Creatinine
Glucose
Magnesium
Total
Bilirubin
Total CO2
Total
Protein
Triglyceride
Urea
Greiner G300 method
Bromocresol green (36 sec.)
(Gustaffson, 3
4-nitrophenyl phosphate (37)
(Kuffer & Richterich [5]
Cresolphthalein complexone
(Kuffer & Degiampietro, 7
Rate reaction/alkaline picrate
(Barrels & Bohmer, [9
Glucose oxidase/PAP
(Trinder, 11 ])
Calmagit
(Khayam-Bashi et al, 13
2, 4 dichloroaniline
(Kuffer & Degiampietro, 15
PEP carboxylase/fast violet B
(Forrester et al, 17
Biuret
(Hoffman & Richterich, 19
Fully enzymatic
(Stavropoulos & Crouch, [21 ])
Urease Berthelo
(Richterich & Kuffer, [23
Comparison method
Equipment Method
Technicon
SMA Plus
Technicon
SMA Plus
Technicon
SMA Plus
Technicon
SMA II
Technicon
SMA II
Pye-Unicam
SP90
Technicon
SMA Plus
Technicon
SMA II
Technicon
SMA Plus
Technicon
AA II
Technicon
SMA II
Bromocresol green (end point)
(Doumas et al, [4
4-nitrophenyl phosphate (37)
(Morgenstern, [6
Cresolphthalein complexone
(Gittelman, 8
End point alkaline picrate
(Chasson et al, 10]
Glucose oxidase/3-MBT
(Gochman & Schmitz, 12
Atomic absorption
(Dawson & Heaton, 14
Sulphanilic acid/caffeine
(Gambino & Schreiber, 16]
Gas dialysis/cresol red
(Skeggs & Hochstrasser, 18
Biuret
(Bigat & Saifer, 20
Dihydrolutidine derivative
(Kessler & Lederer, 22
Diacetyl monoxime
(Marsh et at, 24
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currently used at Addenbrooke’s Hospital, based primarily
on continuous flow equipment.
Precision
The overall precision of the analytical system was assessed
in a series of three experiments: within-batch precision
was assessed by repeated consecutive analysis of the same
materials (four control sera with different concentrations of
each analyte, see Table 4) for each analyte under evaluation;
between batch precision was assessed for most analytes by
blind duplicate analyses of up to 150 patient samples on the
G300. The between-batch precision was further assessed for
four of the analytes selected for evaluation by assaying a
serum pool four or five times on each of the five days of the
study.
Table 3. Frequency of outlier results
Analysis Number of outliers
Creatinine 64
Magnesium 3
Total bilirubin 20
Total protein 13
Accuracy
Results obtained from the G300 for each of seven determin-
ations on between 50 and 150 patient samples were compared
with results obtained from Technicon SMA II and SMA 12/60
systems. Analysis on the G300 followed analysis on Technicon
systems, normally the following day but in some cases a
week-end intervened between the two analyses. Total bilirubin
and total CO2 were excluded from this part of the evaluation
in view of the instability of these constituents during storage.
Insufficient data was available to make valid comparisons
for magnesium and triglyceride.
The methods used for comparison are not offered as
reference methods. However, this laboratory participated in
the UK National Quality Control Scheme and in the Wellcome
Quality Control Scheme. The variance indices of this labora-
tory for the National Quality Control Scheme for the week
in which the evaluation was performed were as follows:-
urea 53 creatinine 17
glucose :33 total bilirubin 45
calcium :72 total protein 21
phosphate 52 albumin :33
The Overall Mean Running Variance Index Score for this
laboratory was 48, which contrasts favourably with the
national average of 60 for the same size of laboratory.
In an attempt to obtain further independent assessment
of accuracy, two batches of Technicon ILCS sera (A4SO97
and B4S 141, Technicon Instruments Ltd. Basingstoke, Hants)
were each assayed 15 times on the G300, and the mean
result obtained for each constituent was compared with the
overall mean value for that constituent found by all the
laboratories participating in the Technicon Inter-Laboratory
Quality Control Scheme.
Carryover
Since the G300 makes a separate sampling motion for each
determination on a particular specimen, carryover between
specimens can only occur between the final sample removed
from the first specimen and the first determination on the
succeeding specimen.. Carryover is therefore maximised if a
determination requiring a high volume of serum (eg creatinine,
60 /.tl) is followed directly by water or a serum with low
levels of all analytes. Carryover between successive specimens
for the same determination is not a problem when multiple
analyses are performed on the G300, because a number of
sampling cycles separates the same determination on succeed-
ing specimens. Carryover by contamination of tubes or
cuvettes is restricted as both are washed twice and dried
before reuse.
A series of experiments was performed with serum con-
raining high levels of all analytes, followed by two or three
cups filled with distilled water which were assayed for all
constituents. Carryover was not found to be significantly
different from zero for any of the analyses undertaken.
(Accordingly detailed results are not shown but are available
if required). Similar findings for the GSA II were reported
by Skinner & Wilding and Carlyle et al [2].
Total number
400
90
197
194
Frequency of outlier (gross error) results
16.0
3.7
10.2
6.7
As all analyses on the G300 were performed on sera with
known values for all constituents or on patient material
assayed in duplicate, grossly deviant results were readily
identified and were looked for. The frequency of occurrence
of such outliers was calculated for each determination and is
shown in Table 3 for the four analytes in which this problem
occurred. Most of these outliers can be recognised by the
system and excluded (see discussion) before result release or
production.
Results
Precision
The estimates of within-batch and between-batch precision,
and the precision of replicate analyses are shown in Tables
4 and 5 after exclusion of the outliers. Total bilirubin and
total CO2 have been excluded from the tables because these
constituents in sera alter during the period between replicate
analyses.
Accuracy
The results of linear regression analysis as applied to the data
from the G300 and Technicon systems on patient sera are
shown in Table 6. Figures and 2 illustrate the best corre-
lation (urea) and the worst correlation (albumin). The
comparison between the G300 results (mean of 15 analyses)
for Technicon ILCS sera A4S097 and B4S141 and the
published overall mean result from all laboratories is shown
in Table 7.
Discussion
Precision
A number of workers have attempted to define acceptable or
target standards of precision for clinical laboratories. Tonks
[26] suggested that the analytical standard deviation should
not exceed 25% of the normal range, leading to an allowable
co-efficient of variation (CV) calculated from the formula:.
Allowable analytical CV 0.25MeanWidth’normalOf normalvaluerange x 100
and further suggested that the maximum allowable analytical
CV be 10%. Cotlove et al [2,7] have postulated that the
analytical coefficient of variation should be less than half the
composite biological coefficient of variation, defined as the
combined variance due to within andbetween person variation.
These criteria are shown in Table 8 for various determinations,
together with the experimentally-determined within-batch
and, between-batch coefficients of variation at the appropriate
level of the analyte concentration. The between-batch
precision attained by the G300 meets Tonks’ criteria where
data is available, and betters the more stringent Cotlove
criteria for all analytes except calcium, magnesium and total
CO2.
Many laboratories find difficulty in achieving the Cotlove
CV for calcium (1.6%). The G300 value of 5.3% for within-
batch calcium CV is seriously worse than the Cotlove criteria
allow and is unacceptable for clinical analysis at this level.
Rather better values are obtained at other levels of calcium
concentration (see Table 4).
The within-batch precision estimates in Table 4 were
performed with the G300 operating as a multiple analyser
for all eleven tests, and thus-successive determinations for
a particular test are not consecutive, but are separated by
ten other sampling motions, each requiring different volumes
of the control serum.
208 Journal of Automatic ChemistryHallworth et al Clinical appraisal of the Greiner G300 clinical chemistry analyser.
Table 4. G300 within-batch precision
Analysis & units Material
(see below)
Mean
value
Albumin g/1 B 23.6
D 30.6
A 41.1
C 43.9
Alkaline B 63
phosphatase u/1 D 174
A 195
C 324
Calcium mmol/1 B 1.73
D 2.29
A 2.53
C 2.92
Creatinine umol/1 B 117
D 158
A 462
C 700
Glucose mmol/1 B 5.0
D 6.2
A 12.5
C 20.0
Magnesium mmol/1 B 0.35
A 0.45
C 0.66
D 0.91
SD
0.34
0.36
0.89
1.1
1.9
4.0
4.1
6.0
0.155
0.065
0.134
0.107
4.6
6.6
8.7
24.0
0.20
0.12
0.20
0.61
0.045
0.051
0.072
0.037
CV (%)
1.5
1.2
2.2
2.4
3.0
2.3
2.1
1.9
9.0
2.8
5.3
3.7
3.9
4.2
3.4
1.9
4.1
2.0
1.6
3.0
13.0
11.4
10.9
4.1
A. Technicon Reference Serum, batch B8G637
B. Technicon ILCS quality control serum, A4S097
C. Technicon ILCS quality control serum, B4S141
D. Wellcomtrol unassayed serum, lot K6314
Table 5. G300 between-batch precision
(a) Standard deviation of duplicate analyses (see text)
Analysis & units
Albumin g/1
Alkaline phosphatase U/1
Calcium mmol/1
Creatinine tmol/1
Glucose mmol/1
Total protein g/1
Urea mmol/1
Number
of pairs (n)
53
53
53
101
145
45
143
SDof
duplicates
0.74
4.06
O.05
9.58
0.43
0.97
0.18
Range of
values
17 43
67 921
1.16 3.26
63 1052
3.2 17.6
53-81
1.3 -45.0
Analysis & units
Total Bilirubin
tmol/1
Total CO2 mmol/1
Total protein g/1
Triglyceride
mmol/1
Urea mmol/1
Material
(see below)
B 12
D 42
A 49
C 107
B 18.0
A 23.2
D 26.2
C. 29.1
B 43.0
A 73.0
D 74.5
C 84.6
B 0.48
D 0.60
C 1.00
A 2.74
B 1.9
A 8.4
D 10.0
C 12.5
Mean SD CV (%) value
0.5
1.0
1.0
1.7
0.74
0.96
0.58
1.16
0.92
1.24
0.91
3.20
0.020
0.015
0.028
0.055
0.09
0.17
0.18
0.17
4.2
2.4
2.1
1.6
4.1
4.1
2.2
4.0
2.1
1.7
1.2
3.8
4.2
2.4
2.8
2.0
4.6
2.0
1.8
1.3
(b) Precision over 5 days (n 21). Material A. (see Table 4)
Analysis & units Mean value SD
Creatinine umol/1 156 11.4
Glucose mmol/1 6.3 0.26
Total CO2 mmol/1 24.7 1.48
Urea mmol/1 10.0 0.21
(Robinson, 25]
Standard deviation /__
/ 2n-1
CV
7.3
4.1
6.0
2.1
20 1E
10
I0 20 30
SA II (rn molll)
Figure 1. Correlation of urea results Greiner G300
versus SMA II.
50
’
40
30
20
10
0 30 40 50 l0 20
SMA PLUS (g/I)
Figure 2. Correlation of albumin results Greiner G300
versus SMA Plus.
Volume 2 No. 4 October 1980 209Hallworth et al Clinical appraisal of the Greiner G300 clinical chemistry analyser.
The standard deviation of duplicate analyses has been
determined for seven determinations (Table 5a). Robinson
[25] states that this parameter usually represents a good
estimate of the between-batch standard deviation, although
it is clearly an average estimate across a range of analytical
concentration. Between-batch precision estimates determined
over five days give similar values (Table 5b).
The precision of the G300 is clinically acceptable for all
determinations, with the possible exception of calcium.
Precision is better than the SMA system used for comparison
for alkaline phosphatase and urea, similar for total protein
and albumin, and worse than the SMA systems for calcium,
creatinine, glucose and total CO2.
Accuracy
The results of the correlation between the G300 and SMA
analysers (Table 4) show that the determinations of alkaline
phosphatase, creatinine, glucose and urea correlate well
(r>0.98). Those for albumin, calcium and total protein
are less ideal, but still greater than 0.94.
The gradients of the regression lines represent lower values
given by the G300 for creatinine, urea, albumin and calcium.
The greater specificity of the G300 determinations for
creatinine (kinetic versus end point Jaff6), urea (enzymatic
versus diacetyl monoxime) and albumin (short versus long
reaction with BCG) is likely to account for much of this and
the Greiner result may more nearly reflect the reference
method result. Calcium methods are the same on both
Table 6. Correlation of results G300 versus Technicon
SMA
Analysis & units Number Correlation Gradient Intercept
coefficient
Albumin g/1 54 0.947 0.967
Alkaline
phosphatase//1
Calcium mmol/1
Creatinine mol/1
Glucose mmol/1
Total protein g/1
Urea mmol/1
54 0.986 1.430
54 0.968 0.963 -0.033
140 0.997 0.896 29.4
150 0.994 0.996 -0.324
52 0.966 0.996 1.54
146 0.998 0.941 0.193
Table 7. Comparison of G300 results with consensus values
for Teehnicon ILCS sera (A serum A4S097, B serum
B4Sl41)
Analysis & units G300 (Mean of Consensus
15 results) Mean SD
Albumin g/1 A
B
Deviation
(SD units)
from consensus
value*
Alkaline A
Phosphatase #/1 B
Calcium mmol/1 A
B
Creatinine A 117
umol/1 B 700
Total CO2 A 18.0
23.7 25.6 1.30 -1.5
43.9 45.7 1.93 -0.9
63.5 47 4.43 +3.7
324 199 15.62 +8.0
1.75 1.79 0.07 -0.8
2.92 2.95 0.09 -0.3
102.7 8.23 +1.7
788.9 33.82 -2.6
mmol/l B 29.0
Total bilirubin A 12.1
mol/1 B 107
Total protein A 43.0
g/1 B 84.6
18.0 1.44 0
30.8 2.11 -0.8
14 1.86 -1.0
116 8.48 -1.0
42.1 1.36 +1.36-
80.9 2.93 +1.3
4.7 0.31 -8.8
28.5 0.91 17.5
Urea mmol/1 A 1.95
B 12.5
*This represents the difference between the G300 mean value and the
consensus mean value expressed as a fraction of the consensus S.D.
machines, so that an explanation of the difference here
probably has to be based on dialysis by one machine and not
by the other.
Values for alkaline phosphatase are significantly higher
on the G300 than on the SMA 12/60 (gradient of regression
line 1.43). The instruments use the same substrate and
reaction temperature (4-nitro phenyl phosphate, 37), but
in different buffer systems (diethanolamine for the G300,
2-amino 2-methyl propan-l-ol for the SMA 12/60). Methods
using the G300 combination of substrate and buffer have
been reported to give elevated values for alkaline phosphatase
(End of Period Report, Wellcome Group Quality Control
Programme, Wellcome Reagents Ltd., March 1979), but this
should not affect the interpretation of results when the
reference range is properly defined.
The G300 results compare reasonably well with the
consensus values reported for Technicon ILCS sera A4S097
and B4S141 (Table 7). All G300 results lie within two
standard deviations of the consensus value, with the exception
of alkaline phosphatase, creatinine and urea. The elevated
alkaline phosphatase results have already been attributed
to the use of diethanolamine buffer, and the discrepant urea
results may be explained by the fact that the diluent used for
Technicon ILCS sera contains ammonia, which interferes
with the urease/phenol/hypochlorite method for urea on the
G300.
Outlier results
As is clear from Table 3, outlier results for creatinine, total
bilirubin and total protein occurred with unacceptable
frequency on the instrument under test. This problem is
compounded when an outlier result is within the linear
range of the instrument, because there is no indication on the
machine output that a fault has occurred unless a result falls
outside pre-defined ranges: outliers which are clinically
feasible are thus undetectable without analysing samples
in duplicate, which is clearly impractical.
In general, since there is no visual contact with the analy-
tical system for much of the time, it is not easy to pinpoint
the cause of random errors. Air bubbles in the photometer
cell or incomplete dispensing of a particular reagent are not
readily detectable. It is possible to examine the raw optical
density data supplied by the photometer, and this is of
undoubted value in tracing certain faults, but the possibility
of random outliers passing undetected was strong. The more
recent production models of the G300 incorporate a photo-
meter system that performs multiple optical density readings
on each cuvette with truncation of exceptional values, and
hence can detect air bubbles and particulate matter. It is,
therefore, possible that the high outlier frequency was unique
to this prototype instrument and recent information indicates
that present models do not have this problem.
Table 8. Relation of G300 precision to published criteria
(see text)
Constituent &
approximate level
Albumin 40 g/1
Alkaline
phosphatase 60 U/1
Calcium 2.5 mmol/1
Creatinine 156 mol/1
Glucose 6.0 mmol/1
Magnesium 0.9 mmol/1
Total bilirubin 15 vmol/1
Total CO2 26 mmol/1
Total protein 70 g/1
Triglyceride 1.0 mmol/1
Urea 10.0 mmol/1
ND not done
Greiner G300 CV (%) Tonks
Within Between
batch
2.2
3.0
5.3
4.2
2.0
4.1
4.2
2.2
1.7
2.8
1.8
batch
CV (%)
Cotlove
CV (%)
ND 10.0 3.5
ND 10.0
ND 6.0 1.6
7.3 10.0
4.1 10.0 4.7
ND 8.8 3.3
ND 10.0
6.0 6.0 3.1
ND 7.0 3.2
ND 10.0
2.1 10.0 7.5
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Calibration
The chemical stability of the G300 in the absence of repeated
calibration is impressive, and provides the opportunity for
considerable reduction of expenditure on calibration material.
The long-term stability of calibration in routine use was not
assessed here.
General performance
Obviously a five-day evaluation period is inadequate to
indicate a long-term reliability of the G300. However, we
were impressed by the ability of the machine to produce
results within 24 hours of arrival in the laboratory, having
been transported considerable distances by road.
There were no mechanical or electronic problems causing
significant down-time during the week in which the instru-
ment was studied.
Conclusion
The Greiner G300 analyser is an efficient discrete analyser
with adequate standards of accuracy and precision. It requires
little sample, and all eleven tests discussed in this evaluation
can be performed on 400/al serum. The manufacturer states
that method sensitivity is such that the same analyses could
be carried out on a pre-diluted sample of serum, such that an
initial 50/al only of serum would be required.
The design of the analyser makes it very easy to perform
only those tests actually requested by the clinician, with
consequent savings of time and reagents. Worklists and
batching of tests are unnecessary. Laboratories with good
ward liaison could therefore significantly reduce their work-
load while providing the same amount .of useful biochemical
information.
The G300 is well suited to paediatric and emergency work,
and could easily handle the combined routine paediatric and
adult emergency analyses for even large hospitals. The capital
cost of the instrument may appear to make it an expensive
solution to providing for these analyses, but substantial staff
savings would be effected.
Throughput is more than adequate for single analyses
but becomes slow in comparison to other equipment if more
than five or six analyses per specimen are required.
The G300 should be capable of handling the major analy-
tical workload for laboratories with a total workload of
500,000 requested tests. It was not designed for, and is not
suitable for, laboratories committed to a large ’profiling’
workload.
With improved elimination of outlier results, the G300
provides a convenient and reliable solution to the problems
of smaller hospitals with modest workloads spread over a
variety of analyses. It is capable of providing a rapid paedia-
tric and emergency service for even the largest hospitals.
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